Scientists are developing methods to produce extremely rare Rh null blood in laboratory settings after discovering it exists in only 50 individuals globally. University of Bristol professor Ash Toye and colleagues successfully generated the blood type through gene editing techniques that removed antigens from five major incompatibility groups, creating cells compatible with most recipients including those carrying the exceptionally scarce Bombay phenotype affecting one person per four million.
Multiple research teams have employed CRISPR-Cas9 technology to manufacture the valuable blood variant from various stem cell sources, though commercial production remains years away due to technical challenges in achieving mature red blood cell development outside bone marrow environments. Toye established Scarlet Therapeutics to collect donations from rare blood type carriers for creating perpetual laboratory cell lines without genetic modification.
The RESTORE clinical trial represents the first human testing of artificially cultivated red blood cells from donor stem material, marking a decade of preparatory research before reaching volunteer studies. Researchers acknowledge that traditional donation methods will continue serving general needs while laboratory production could eventually supply emergency reserves for individuals possessing uncommon blood characteristics.
Multiple research teams have employed CRISPR-Cas9 technology to manufacture the valuable blood variant from various stem cell sources, though commercial production remains years away due to technical challenges in achieving mature red blood cell development outside bone marrow environments. Toye established Scarlet Therapeutics to collect donations from rare blood type carriers for creating perpetual laboratory cell lines without genetic modification.
The RESTORE clinical trial represents the first human testing of artificially cultivated red blood cells from donor stem material, marking a decade of preparatory research before reaching volunteer studies. Researchers acknowledge that traditional donation methods will continue serving general needs while laboratory production could eventually supply emergency reserves for individuals possessing uncommon blood characteristics.
